Will Garvin, shareholder and co-head of Buchanan's cannabis group, comments on the challenges the U.S. Food and Drug Administration (FDA) is facing in regulating products containing cannabidiol or CBD in S&P Global Market Intelligence article, "US FDA grapples with dosing, drug interaction questions in new CBD terrain."            

"Garvin argued that while anecdotal information does not rise to the level of well-run clinical trials, it nonetheless remains useful about whether there are adverse events or therapeutic benefits. "If the use of these products lessens the impact of opioid dependency, then that would be something that would have a prevailing good for the public health that FDA should investigate," Garvin told S&P Global Market Intelligence. But he emphasized that "first and foremost, the FDA is a public health institution of government and so they should focus primarily on science."